Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease

Summary

For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance. There are no known treatments that can either prevent or reverse its progression. Consequently, there still remains a need to evaluate treatments which can better stabilize the symptoms of this disease. These symptoms frequently include decreased functional capacity and negative psychological attributes (e,g, depression, anxiety) in association with the memory and cognition deficits. This current study is being done to assess an investigational compound that has been designed to not only improved the cognitive status of affected patients but to also better manage all symptoms. Hence, the ultimate goal is to provide patients with an improved quality of life by slowing the progression of this neurodegenerative disease

Timeline

Start

2011-02

Primary completion

2012-09

Completion

2013-03

Outcome

Missed primary endpoint

registry analysis (superiority test); Ladostigil Hemitartrate vs Placebo; p <0.67; ANCOVA NCT01354691 ↗

Drugs

Indications